By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose…

By:  Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s…

By: Elsa Thomas, Pharm.D. c/o 2013 – Human body uses various complex mechanisms to maintain its body temperature within a narrow range despite extreme environmental temperature changes as well as physiological changes. Several factors can affect body temperature such as disease states, growth, exercise, hormonal changes, and medications. Hypothermia can occurs as a result of…

By: Jena Marion, Pharm.D. Candidate c/o 2013 – I have traveled a lot these past few years.  I have packed and unpacked suitcases, measured three-ounce bottles of liquids, and printed plenty of boarding passes.  Most of my trips were for business, but a few were for pleasure.  Pharmacy, however, followed me along on each one…

By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes.  Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a…